Asset
SOTAGLIFLOZIN
Lexicon Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (28)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02531035 | phase3 | completed | 2015-09-01 | 2017-04-01 | Lexicon Pharmaceuticals | A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone |
| NCT03242018 | phase3 | completed | 2017-08-16 | 2019-05-16 | Lexicon Pharmaceuticals | A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control |
| NCT06481891 | phase3 | active_not_recruiting | 2024-09-24 | 2027-01-01 | Lexicon Pharmaceuticals | A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy |
| NCT01441232 | phase1 | completed | 2011-10-01 | 2011-11-01 | Lexicon Pharmaceuticals | A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics |
| NCT02373046 | phase1 | completed | 2015-02-01 | 2015-04-01 | Lexicon Pharmaceuticals | Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 216203 | NDA | LEXICON PHARMACEUTICALS INC |
Marketed products (2)
- INPEFA
- INPEFA